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The neurotoxic effect of amyloid-β peptide (Aβ) over the central synapses has been
described and is reflected in the decrease of some postsynaptic excitatory proteins, the
alteration in the number and morphology of the dendritic spines, and a decrease in long-
term potentiation. Many studies has been carried out to identify the putative Aβ receptors
in neurons, and is still no clear why the Aβ oligomers only affect the excitatory synapses.
Aβ oligomers bind to neurite and preferentially to the postsynaptic region, where the post-
synaptic protein-95 (PSD-95) is present in the glutamatergic synapse, and interacts directly
with the N -methyl-D-aspartate receptor (NMDAR) and neuroligin (NL). NL is a postsynaptic
protein which binds to the presynaptic protein, neurexin to form a heterophilic adhesion
complex, the disruption of this interaction affects the integrity of the synaptic contact. Struc-
turally, NL has an extracellular domain homolog to acetylcholinesterase, the first synaptic
protein that was found to interact with Aβ. In the present review we will document the
interaction between Aβ and the extracellular domain of NL-1 at the excitatory synapse, as
well as the interaction with other postsynaptic components, including the glutamatergic
receptors (NMDA and mGluR5), the prion protein, the neurotrophin receptor, and the α7-
nicotinic acetylcholine receptor. We conclude that several Aβ oligomers receptors exist at
the excitatory synapse, which could be the responsible for the neurotoxic effect described
for the Aβ oligomers. The characterization of the interaction between Aβ receptors and Aβ
oligomers could help to understand the source of the neurologic damage observed in the
brain of the Alzheimer’s disease patients.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common form of demen-
tia with a high prevalence rate among the aging population, and
recent estimates suggest that it affects about 35 million individuals
worldwide (Querfurth and LaFerla, 2010). Clinical manifestations
are characterized by loss of selective cognitive functions, partic-
ularly memory, loss that begins early in the disease progression
(Selkoe, 2002; Ballard et al., 2011). These traits are accompa-
nied by neuropathological features observed in postmortem AD
brains. Studies of AD brains have revealed the presence of the
classical neuropathological hallmarks, neurofibrillary tangles, and
senile plaques (Haass and Selkoe, 2007). These senile plaques
are aggregates of amyloid-β peptide (Aβ) which are deposits in
brain areas involved in cognitive functions and it is assumed
that they initiate a pathological cascade that results in synap-
tic dysfunction, synaptic loss, and neuronal death (Haass and
Selkoe, 2007; Cerpa et al., 2008). Aβ spontaneously self aggregates
into multiple coexisting physical forms. One of them consists of
oligomers (ranging from dimers to dodecamers) which coalesce
into intermediate assemblies. Fibrils, which arrange themselves
into β-pleated sheets to form the insoluble fibers of advanced amy-
loid plaques. Soluble oligomers and intermediate amyloid are the
most neurotoxic forms (Klein et al., 2001; Kayed et al., 2003).
It is known that synapses are lost during Alzheimer’s and there
is a high correlation between synaptic loss and cognitive decline
observed in AD patients (Serrano-Pozo et al., 2011). Aβ oligomers
selectively block long-term potentiation (LTP) and acutely dis-
rupt cognitive function after infusion into the central nervous
system (CNS; Haass and Selkoe, 2007; Cerpa et al., 2008). They
also bind with a punctuate pattern to postsynaptic excitatory pyra-
midal neurons but not to GABAergic neurons (Lacor et al., 2004)
and lead to synaptic loss (Wei et al., 2010). In both AD patients
and animal models of the disease, synapse loss is greatest near to
senile plaques, indicating a link between amyloid pathology and
synaptotoxicity in vivo (Lacor et al., 2004; Wei et al., 2010). There
is considerable evidence that specificity of Aβ binding at neuronal
surfaces and synapses requires membrane proteins, and several
candidate receptors that may have an important role in expression
of Aβneurotoxicity have been postulated as potential targets for Aβ
(Table 1). The objective of this article is to review the interactions
between soluble Aβ oligomers and specific neuronal postsynaptic
receptors in the context of Aβ-mediated synaptic disruption and
neurotoxicity.
GLUTAMATE RECEPTOR AS A MEDIATOR OF Aβ TOXICITY
Synaptic degeneration, including loss of synapses in the brain
and the consequent impairment in synaptic plasticity, is the best
morphological correlate of cognitive impairment in clinical AD
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α7AChR 42 Monomer 4.1 pM Wang et al.
(2000)
α4β2AChR 42 Monomer 30 nM
AChE 12–48 fragment – Alvarez
et al. (1997)
Fz5-CRD 40 Monomer 0.105µM Magdesian
et al. (2008)
Fz5-CRD 42 Monomer –
Fz5-CRD ADDL –
Fz5-CRD Fibril –
PrPc Oligomer 92 nM Lauren
et al. (2009)
NMDAR ADDL – De Felice
et al. (2007)
TNF-R 40 Monomer 4.2 pM Li et al.
(2011)
α2β1 integrin 40 Monomer – Wright et al.
(2007)
αVβ1 integrin 40 Monomer –
APP Fibril – Lorenzo
et al. (2000)
NL-1 Monomer/oligomer 0.75µM Dinamarca
et al. (2011)
TheTable presents the main putative receptors that bind or interact with different
types of Aβ aggregates, in some cases the dissociation constant (Kd) is included.
In other cases, it shows protein that are not receptors, for example AChE and the
APP, both proteins interacts with Aβ aggregates.
(Terry et al., 1991; Sze et al., 1997). It has been demonstrated
that cognitive impairments in learning and memory are related to
degenerative synaptic changes produced by the presence of soluble
Aβ oligomers in vulnerable brain regions such as the hippocampus
(Lambert et al., 1998; Walsh and Selkoe, 2004; Almeida et al., 2005;
Haass and Selkoe, 2007). Glutamatergic neurotransmission has
an essential role in synaptic transmission and neuronal plasticity
processes associated with learning and memory (Bard and Groc,
2011). Impairment in glutamatergic neurotransmission signaling
has been described as an important factor in AD pathology (Snyder
et al., 2005; Yamin, 2009; Proctor et al., 2011). Glutamate receptors
consist of two classes: ionotropic and metabotropic, members of
both classes have been implicated as putative neuronal receptors
that mediate Aβ oligomer neurotoxicity.
N -METHYL-D-ASPARTATE RECEPTORS
N -methyl-D-aspartate receptors (NMDARs) located at the post-
synaptic density of dendritic spines play key roles in glutamatergic
transmission and synaptic plasticity in the CNS. These receptors
are important for induction of LTP and synaptic transmission
(Snyder et al., 2005; Bordji et al., 2011; Proctor et al., 2011).
A number of studies have shown that Aβ can affect the func-
tion of NMDARs and abolish induction of NMDAR-dependent
LTP at the neuronal plasma membrane (Snyder et al., 2005;
Shankar et al., 2007). Aβ binds to NR1 and NR2B subunits of
the hippocampal neurons NMDAR (Lacor et al., 2004, 2007). Aβ
oligomers induce the endocytosis of NMDA receptors by a α7-
nicotinic acetylcholine receptor (α7-nAChR)-dependent manner
(Snyder et al., 2005). Also α7-nAChRs are involved in deregulation
of NMDA signaling pathways (Roselli et al., 2005; Shankar et al.,
2007). In synaptosomes, Aβ oligomers co-immunoprecipitated
with NMDAR subunits and partially (50%) co-localize, in hip-
pocampal slices (De Felice et al., 2007; Deshpande et al., 2009;
Renner et al., 2010; Rönicke et al., 2011). However, it is unclear
the domain to which Aβ directly binds to NMDAR subunits. The
NR2B subunit of NMDAR has been implicated in regulating the
action of Aβ oligomers by increased intracellular calcium into
dendritic spines resulting in reduced dendritic spine and synaptic
density that led to early synaptic dysfunction (Shankar et al., 2007).
Also, the stimulation of NR2B by Aβ oligomer triggers the acti-
vation of MAPK and the subsequent down-regulation of CREB
(Li et al., 2011). Interestingly, relatively low doses of NMDA-
antagonists have been reported to reverse Aβ-induced synaptic
disruption (Li et al., 2011; Rönicke et al., 2011). In addition, Aβ
has been shown to decreased formation clusters at the postsynaptic
membrane, reducing levels of scaffolding proteins such as PSD-95,
which has an important role in synaptic plasticity and stabiliza-
tion of glutamate receptors located at excitatory synapses. Also,
this dysfunction has been associated to an enhancement of NR2A
activity (Liu et al., 2010). Moreover, in hippocampal neurons
Aβ oligomers disrupts axonal transport initiated by NMDAR-
dependent mechanisms and mediated by the enzyme glycogen
synthase kinase-3β (GSK-3β; Decker et al., 2010). Therefore, dif-
ferent pathways related to NMDARs, are in direct or indirect way
involved in the neurotoxicity mediated by the Aβ oligomers.
METABOTROPIC GLUTAMATE RECEPTOR 5 (mGluR5)
The GluR5 subtype of metabotropic glutamate receptors located
at the neck of dendritic spines has important regulatory roles in
excitatory synaptic transmission at hippocampal synapses, includ-
ing modulation of LTP and potentiation of NMDAR-mediated
calcium influx (Renner et al., 2010). A recent study identified
mGluR5 as a novel neuronal receptor target for Aβ using sin-
gle particle tracking of quantum dot labeled Aβ oligomers on
hippocampal neurons, and examining their interactions with
mGluR5 receptors. Membrane-bound Aβ oligomers accumulated
at synaptic space, where they progressively aggregated to form large
non-mobile clusters through lateral diffusion. Pathological clus-
ters of Aβ formed complexes with mGluR5 receptors, leading to
decreased mobility of mGluR5 and causing their aberrant accumu-
lation at the postsynaptic membrane. This was followed by calcium
deregulation, synaptic disruption, and loss of NMDARs, suggest-
ing that their role in early synaptic impairment is induced by Aβ
(Renner et al., 2010). Interestingly, mouse hippocampal neuronal
cultures from mGluR5-knockout mice revealed an approximately
80% decrease in Aβ binding to the neuronal surface and a loss of
NMDARs from the cell surface (Renner et al., 2010). mGluR sig-
naling is down-regulated and desensitized in the frontal cortex of
AD patients and has been shown to correlate with AD related
neuropathological changes. Moreover, mGluR5 shares a func-
tional relationship with NMDAR, in particular because it relates
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to development of NMDA-dependent LTP and learning (Rammes
et al., 2011). Furthermore, chronic activation of mGluR5 increases
NMDA-dependent Aβ neurotoxicity, whereas its inhibition shows
neuroprotective effects against Aβ excitotoxic processes (Rammes
et al., 2011). Thus, there is persuasive experimental evidence that
Aβ oligomers are able to influence glutamatergic transmission by
affecting both NMDAR and mGluR5 receptors. Therefore antag-
onists of these receptors have become promising targets for the
treatment of AD. Memantine (a non-selective NMDAR antago-
nist) is currently being used in clinical practice for the treatment
of patients with moderate to advanced AD (De Felice et al., 2007).
p75 NEUROTROPHIN RECEPTOR IN Aβ OLIGOMER
NEUROTOXICITY
p75 is a transmembrane glycoprotein and low-affinity nerve
growth factor (NGF)-receptor, member of the tumor necrosis
factor receptor superfamily, which binds all neurotrophins with
similar affinity but different kinetics (Dechant and Barde, 2002),
neurotrophins have diverse functions in the CNS, initially syn-
thesized as precursors (proneurotrophins), they are cleaved to
produce mature proteins, which promote neuronal survival and
enhance synaptic plasticity by activating Trk receptor tyrosine
kinases. The broad spectrum of biological activities exerted by
the neurotrophins results from their ability to bind and activate
two structurally unrelated receptor types, the p75-NTR, and the
three members (in mammals) of the Trk receptor family of tyro-
sine kinases (Dechant and Barde, 2002). The various functions of
p75-NTR depend on the type of ligand bound to it, the cell type in
which it is expressed and the presence or absence of Trk receptor.
p75 induces the neurotrophin NGF mediated survival in neuronal
cells expressing TrkA. Moreover, neurons expressing p75-NTR
without co-expressing Trk underwent apoptosis upon NGF treat-
ment (Dechant and Barde, 2002). In addition, p75-NTR mediates
a range of neurobiological functions, including cell fate, axon
guidance, and modulation of neurite outgrowth (Barker, 2004). It
has been demonstrated that all neurotrophins that activated p75,
without co-activation of the relevant Trk co-receptor, mediated
apoptosis in hippocampal neurons. Thus, proneurotrophins and
Aβ can induce p75-mediated apoptosis in hippocampal neurons
since they do not bind or activate Trk receptors. The p75-mediated
Aβ cytotoxicity mechanism involves the downstream activation of
p75 intracellular death domain (Diarra et al., 2009). The death
domain in turn activates G0 subtypes of G protein, which leads
to c-Jun N-terminal kinases (JNK) phosphorylation. Although
there are many pathways hypothesized, most of the sources found
the terminal outcome of this process to be cell death (Coulson,
2006). These findings were confirmed by another group who
found that hippocampal neurons became apoptotic after Aβ1−42
treatment (Sotthibundhu et al., 2008). Therefore, hippocampal
neurons undergo neurotrophin-dependent p75-mediated apop-
tosis in the absence of Trk co-activation. Ligands that activate p75
but not Trk, such as Aβ and proneurotrophins, might contribute
to the pathogenesis of AD. However, it remains to be determined
which of these ligands has the most impact in disease pathogen-
esis. It is also worth determining whether reducing level of such
ligand can alleviate pathogenesis of AD.
α7-nAChR AS A MEDIATOR OF Aβ TOXICITY
Since the 1970s it has been proposed that the cholinergic system
plays an important role in the pathogenesis of AD. Early studies
indicate that in patients who have the disease, there is a decrease in
the number of cholinergic neurons (Davies and Maloney, 1976;
Whitehouse et al., 1982), a decrease in acetylcholine synthesis
(Sims et al., 1983), a reduced number of cholinergic receptors in
the cortex (White et al., 1977; Kellar et al., 1987), reduced acetyl-
cholinesterase (AChE) activity (Perry et al., 1978a), and increased
butyryl-cholinesterase (BuChE) activity (Perry et al., 1978b; Bar-
tus et al., 1982). These discoveries led to propose the “cholinergic
hypothesis of AD,” in which the lacks of acetylcholine was respon-
sible for triggering AD pathology, therefore specific drugs were
selected by their capacity to increase acetylcholine, including AChE
and BuChE inhibitors or nAChR agonists (Bartus et al., 1982; Man-
gialasche et al., 2010). Interestingly those neurons which express
abundant α7-nAChR are more vulnerable to damage by Aβ1–42,
the most neurotoxic form of Aβ, this could be due to their strong
physical interaction (Wang et al., 2000), and/or to the receptor
internalization allows with the Aβ peptide bound to it (Nagele
et al., 2002). This would explain the accumulation of large amounts
of the Aβ peptide in the perikaryon of pyramidal neurons of the
forebrain observed previously of Aβ deposition (D’Andrea et al.,
2002). Also of interest is the association of the α4 and α7 sub-
units of the nicotinic receptor to the senile plaques present in AD
brains (Wevers et al., 1999). Moreover, it has been suggested that
the α7-nAChR expressed in the smooth muscle of brain blood
vessels in AD patients, allows a greater deposition of Aβ1–42 pep-
tide responsible for the amyloid angiopathy present in AD brains
(Clifford et al., 2008). In Caenorhabditis elegans, it has been shown
that the Aβ peptide expressed in the nematode muscle triggers
a mislocalization and a synaptic dysfunction of the ACR16, the
homolog receptor protein of α7-nAChR in the worm (Rebolledo
et al., 2011).
Currently there is evidence in the literature supporting the
idea that the Aβ peptide acts as an agonist or antagonist of nico-
tinic receptors (Buckingham et al., 2009). In fact, Aβ1–42 interferes
the signaling of different nicotinic receptors in Xenopus oocytes
(Lamb et al., 2005). In rat hippocampal slices, acetylcholine cur-
rents mediated by nicotinic receptors of interneurons are inhibited
when they are incubated with nM concentrations of the Aβ pep-
tide (Pettit et al., 2001). Supporting its role as agonist, Dougherty
et al. (2003) shows a calcium increase after exposure hippocam-
pal presynaptic nerve endings to the Aβ peptide. Early studies
indicated also in the α7-nAChR expressed in Xenopus oocyte that
small amounts of Aβ peptide (10–100 pM), would act as an ago-
nist, however larger amounts (100 nM) produces a desensitization
of the receptor (Dineley et al., 2002). On the other hand, it has been
observed that the Aβ peptide can affect downstream nAChR recep-
tor signaling. One example is when Aβpeptide throughα7-nAChR
triggers a down-regulation of the ERK2/MAPK pathway, which has
been associated with memory formation (Dineley et al., 2001).
Supporting this data, post mortem analysis of AD and Down syn-
drome brains showed an increase in the phosphorylation of ERK
protein (Swatton et al., 2004). In addition other studies suggest
that tau phosphorylation, triggered by the Aβ peptide is mediated
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through the α7-nAChR by the activation of GSK-3β (Hu et al.,
2008; Bitner et al., 2009) and also to the activation of the JNK
and ERK (Wang et al., 2003; Schliebs and Arendt, 2011). The Aβ
peptide also produces an increase in the phosphorylation of Akt
(p-Akt) in acute treatment of primary neurons in culture, in a
manner NMDAR and α7-nAChR dependent. However, chronic
exposure to the Aβ peptide leads to a decrease of p-Akt levels. In
old transgenic AD model (APPswe/PSEN1∆E9), the active enzyme
levels were considerably lower than in wild-type mice (Abbott
et al., 2008). Akt phosphorylation has been associated with a pro-
survival function, and alterations in this pathway are associated
with an increased in the severity of AD (Lee et al., 2009).
PRION AS AN AMYLOID RECEPTOR
Cellular prion protein is a glycosyl phosphatidylinositol (GPI)-
anchored cell surface protein (Varela-Nallar et al., 2006). Recently,
it has been suggested that the binding of Aβ oligomer to cellular
prion protein (PrPc) is essential for synaptic toxicity reflected
in the loss of LTP (Lauren et al., 2009). Moreover, ablation of
PrPc enhances cognitive function in transgenic mice overexpress-
ing mutant amyloid precursor protein (APP) gene (APPswe and
PS1∆E9) preventing premature death of neurons and memory
impairment (Gimbel et al., 2010). However, other reports ques-
tioned these findings because the absence of PrPc did not prevent
Aβ oligomer-mediated synaptic toxicity or cognitive impairment
(Balducci et al., 2010; Calella et al., 2010; Kessels et al., 2010).
However, these results confirm the physical interaction between
Aβ and PrPc, however it remains unclear the role of PrPc in this
pathology, for this, more studies are necessary to establish whether
PrPc is essential for the Aβ oligomer neurotoxicity. Recently, it has
been reported that neuronal cell death induced by synthetic Aβ
oligomer was prevented by reducing or eliminating PrPc, or block-
ing the binding between PrPc and Aβ oligomer using either a PrPc
antibody or a decoy PrPc peptide (Kudo et al., 2011). Additionally,
FIGURE 1 | Postsynaptic receptors for Aβ oligomers affect different
signaling pathways.The scheme shows that the binding of Aβ oligomers to
different postsynaptic receptors might trigger synaptotoxicity and consequent
neuronal death by activating different signaling pathways, as indicated, only in
the case of NL-1 (neuroligin-1) and the PrPc (cellular prion protein), the precise
pathway is not known. p75 (p75 receptor of neurotrophin), α7-nAChR
(α7-nicotinic acetylcholine receptor), NMDAR (N -Methyl-D-aspartate
receptor), and mGluR (metabotropic glutamate receptors), the signaling
pathway is already known. In the case of the α7-nAChR, recent studies from
our laboratory also implicated the Wnt signaling pathway.
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it has been described that PrPc participates in Aβ transcytosis
across the blood-brain barrier (Pflanzner et al., 2012). In sum-
mary, the interaction between PrPc and Aβ is very interesting,
because both are pathogenic proteins responsible of neurode-
generative diseases and this particular relationship reinforce the
idea of crosstalk between protein misfolded in neurodegeneration
process (Morales et al., 2010; Forloni and Balducci, 2011).
NEUROLIGIN-1 AS A TARGET FOR Aβ OLIGOMERS
Postsynaptic neuroligins, and their related presynaptic receptors
neurexins (NRXs), are two families of synapse-specific adhesion
molecules critically involved in establishing CNS connectivity
(Dean and Dresbach, 2006; Südhof, 2008). NL is a transmembrane
protein type I with three domains, an extracellular cholinesterase-
like domain, a single transmembrane helix, and a cytoplasmic
C-terminal domain that contains a type I PDZ-binding motif
which interacts with the third PDZ domain of PSD-95 protein
(Scholl and Scheiffele, 2003). However, not just the known NLs
PDZ domain is important in NLs function, recently a new non-
PDZ domain on the cytoplasmic tail has been described as an
essential element for the postsynaptic functional effects of NLs at
excitatory synapses (Shipman et al., 2011). There are four types
of NLs: NL-1 is enriched in glutamatergic excitatory synapses,
while NL-2 is present in GABAergic inhibitory synapses. On the
other hand, NL-3 and NL-4 have been found in both synapses;
also, NL-4 has been found in extraneuronal tissues (Scheiffele
et al., 2000; Dean and Dresbach, 2006). Initially NLs were identi-
fied as ligands for β-neurexin; thereby a role in mediate cell–cell
adhesion was proposed. Disruption of NLs–NRX signaling pre-
cipitates a broad range of cognitive deficits, including motor,
learning, and social impairments (Blundell et al., 2010; Dahlhaus
and El-Husseini, 2010; Dahlhaus et al., 2010), and specific NL
and NRX mutations have been implicated in autism (Südhof,
2008). NLs were shown to be sufficient to induce the forma-
tion of new functional presynaptic terminals in vitro, suggesting
a key role in the specification and consolidation of the synapse
(Dean and Dresbach, 2006). Considerable evidence links NL–NRX
signaling to synapse initiation. In an assay of artificial synaptoge-
nesis, NL-1 expressed in non-neuronal cells is sufficient to induce
presynaptic differentiation in contacting axons of co-cultured neu-
rons (Scheiffele et al., 2000). Moreover, NL-1 overexpression in
primary neuronal cultures potently increases synapse densities
and can increase spontaneous miniature postsynaptic current fre-
quencies, while NL-1 knockdown inhibits normal synaptogenesis
(Dean and Dresbach, 2006; Shipman et al., 2011). NL-1 deletion
strongly impairs neurotransmission while minimally impacting
synapse densities, suggesting that NL-1 may primarily contribute
to synapse function and not formation (Blundell et al., 2010). On
the other hand, it is known that synapses are lost during Alzheimer
and there is a high correlation between synaptic lost and cogni-
tive decline observed in AD patients (Terry et al., 1991; Walsh
and Selkoe, 2004; Serrano-Pozo et al., 2011). Growing evidence
from numerous laboratories suggest that soluble Aβ oligomers,
more than monomers or fibrils, are responsible for Aβ cytotox-
icity (Haass and Selkoe, 2007; Li et al., 2011). As we have been
discussed along this review, several receptor proteins have been
proposed to be capable of binding various forms of Aβ, thereby
inducing its cellular effecs. We had presented both biochemical and
physicochemical evidence in vitro indicating that NL-1 binds to
Aβ oligomers, this interaction occurs in the extracellular domain
of NL-1, suggesting that NL-1 could be a putative target for Aβ
oligomers at excitatory synapse. No effect was observed with NL-2
which is a specific NL form for inhibitory synapses. Given the
important roles of NL-1 as an adhesion protein on the post-
synaptic membrane, the interaction with Aβ oligomers can be
relevant for the stability and the maintenance of synaptic trans-
mission (Dinamarca et al., 2011). Moreover, the fact that NL-1,
a postsynaptic protein forms an heterophilic adhesion complex
with Neurexin, a presynaptic protein, indicates that any disrup-
tion of this interaction might affects the integrity of the excitatory
synaptic contact.
CONCLUSION
The evidence presented in this review, for the interaction among
Aβ oligomers with different synaptic proteins and receptors
is a key contribution to the understanding of the develop-
ment of early AD (Figure 1). In fact, a depth understanding
of how these Aβ-interacting synaptic proteins influence synap-
tic plasticity and memory processes would help to elucidate
the mechanisms by which soluble Aβ oligomers cause neu-
ronal receptor dysfunction and triggers the disease. Hopefully,
all these studies will set an scenario where new therapeutic
strategies emerge to help to develop new an effective treatments
for AD.
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